ScinoPharm Taiwan, Ltd.
台灣神隆股份有限公司
ScinoPharm Taiwan, Ltd. is a Taiwan TWSE-listed biotechnology company; its most advanced asset is Bortezomib (TFDA approved; NHI reimbursement included, Multiple myeloma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| Bortezomib | — | TFDA approved; NHI reimbursement included | Multiple myeloma | Taiwan | 2026-08-17 | Company disclosure |
| Clofarabine | — | FDA approved | Acute lymphoblastic leukemia | United States | 2026-03-19 | Company disclosure |
| Glatiramer Acetate | — | Shipments to the U.S. started | Multiple sclerosis | United States | 2026-08-17 | Company disclosure |
Key events
No verified events in the past twelve months.